Moreover, MS is a heterogeneous group of diseases without specific biomarkers, and examining the group of cases with positive MOG antibodies and positive OCBs may lead to elucidation of the pathophysiology of inflammatory diseases of the CNS, including MS, as a spectrum. This evidence concerns the gene MOG and myeloid sarcoma.